583 related articles for article (PubMed ID: 26921100)
1. Monoclonal antibodies and immune therapies for adult precursor B-acute lymphoblastic leukemia.
Sikaria S; Aldoss I; Akhtari M
Immunol Lett; 2016 Apr; 172():113-23. PubMed ID: 26921100
[TBL] [Abstract][Full Text] [Related]
2. New monoclonal antibodies for the treatment of acute lymphoblastic leukemia.
Farhadfar N; Litzow MR
Leuk Res; 2016 Oct; 49():13-21. PubMed ID: 27521873
[TBL] [Abstract][Full Text] [Related]
3. Novel immunotherapies for adult patients with B-lineage acute lymphoblastic leukemia.
Wei G; Wang J; Huang H; Zhao Y
J Hematol Oncol; 2017 Aug; 10(1):150. PubMed ID: 28821272
[TBL] [Abstract][Full Text] [Related]
4. The ABCs of Immunotherapy for Adult Patients With B-Cell Acute Lymphoblastic Leukemia.
Horvat TZ; Seddon AN; Ogunniyi A; King AC; Buie LW; Daley RJ
Ann Pharmacother; 2018 Mar; 52(3):268-276. PubMed ID: 29025266
[TBL] [Abstract][Full Text] [Related]
5. Future of Therapy in Acute Lymphoblastic Leukemia (ALL)--Potential Role of Immune-Based Therapies.
Kebriaei P; Poon ML
Curr Hematol Malig Rep; 2015 Jun; 10(2):76-85. PubMed ID: 25899862
[TBL] [Abstract][Full Text] [Related]
6. Redirecting T cells to eradicate B-cell acute lymphoblastic leukemia: bispecific T-cell engagers and chimeric antigen receptors.
Aldoss I; Bargou RC; Nagorsen D; Friberg GR; Baeuerle PA; Forman SJ
Leukemia; 2017 Apr; 31(4):777-787. PubMed ID: 28028314
[TBL] [Abstract][Full Text] [Related]
7. Emerging role of immunotherapy in precursor B-cell acute lymphoblastic leukemia.
Valecha GK; Ibrahim U; Ghanem S; Asti D; Atallah JP; Terjanian T
Expert Rev Hematol; 2017 Sep; 10(9):783-799. PubMed ID: 28666090
[TBL] [Abstract][Full Text] [Related]
8. Novel Therapeutic Strategies in Acute Lymphoblastic Leukemia.
Dias A; Kenderian SJ; Westin GF; Litzow MR
Curr Hematol Malig Rep; 2016 Aug; 11(4):253-64. PubMed ID: 27101015
[TBL] [Abstract][Full Text] [Related]
9. Antibodies: Immunoconjugates and autologous cellular therapy in acute lymphoblastic leukemia.
Advani A
Best Pract Res Clin Haematol; 2015; 28(2-3):116-23. PubMed ID: 26590768
[TBL] [Abstract][Full Text] [Related]
10. How should we treat a patient with relapsed Ph-negative B-ALL and what novel approaches are being investigated?
Gökbuget N
Best Pract Res Clin Haematol; 2017 Sep; 30(3):261-274. PubMed ID: 29050699
[TBL] [Abstract][Full Text] [Related]
11. Monoclonal antibodies in adult acute lymphoblastic leukemia.
Kantarjian H
Hematology; 2012 Apr; 17 Suppl 1():S52-4. PubMed ID: 22507779
[TBL] [Abstract][Full Text] [Related]
12. Humoral and cellular immunotherapy in ALL in children, adolescents, and young adults.
Hochberg J; El-Mallawany NK; Cairo MS
Clin Lymphoma Myeloma Leuk; 2014 Sep; 14 Suppl():S6-13. PubMed ID: 25486958
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy in pediatric B-cell acute lymphoblastic leukemia.
Wyatt KD; Bram RJ
Hum Immunol; 2019 Jun; 80(6):400-408. PubMed ID: 30716352
[TBL] [Abstract][Full Text] [Related]
14. Progress and Innovations in the Management of Adult Acute Lymphoblastic Leukemia.
Jabbour E; Pui CH; Kantarjian H
JAMA Oncol; 2018 Oct; 4(10):1413-1420. PubMed ID: 29931220
[TBL] [Abstract][Full Text] [Related]
15. Emerging biological therapies to treat acute lymphoblastic leukemia.
Huguet F; Tavitian S
Expert Opin Emerg Drugs; 2017 Mar; 22(1):107-121. PubMed ID: 27820973
[TBL] [Abstract][Full Text] [Related]
16. Novel immunotherapies in lymphoid malignancies.
Batlevi CL; Matsuki E; Brentjens RJ; Younes A
Nat Rev Clin Oncol; 2016 Jan; 13(1):25-40. PubMed ID: 26525683
[TBL] [Abstract][Full Text] [Related]
17. Should immunologic strategies be incorporated into frontline ALL therapy?
Rank CU; Stock W
Best Pract Res Clin Haematol; 2018 Dec; 31(4):367-372. PubMed ID: 30466749
[TBL] [Abstract][Full Text] [Related]
18. Harnessing the Immune System Against Leukemia: Monoclonal Antibodies and Checkpoint Strategies for AML.
Masarova L; Kantarjian H; Garcia-Mannero G; Ravandi F; Sharma P; Daver N
Adv Exp Med Biol; 2017; 995():73-95. PubMed ID: 28321813
[TBL] [Abstract][Full Text] [Related]
19. T-cell responses against CD19+ pediatric acute lymphoblastic leukemia mediated by bispecific T-cell engager (BiTE) are regulated contrarily by PD-L1 and CD80/CD86 on leukemic blasts.
Feucht J; Kayser S; Gorodezki D; Hamieh M; Döring M; Blaeschke F; Schlegel P; Bösmüller H; Quintanilla-Fend L; Ebinger M; Lang P; Handgretinger R; Feuchtinger T
Oncotarget; 2016 Nov; 7(47):76902-76919. PubMed ID: 27708227
[TBL] [Abstract][Full Text] [Related]
20. Novel antibody therapy in acute lymphoblastic leukemia.
Kochuparambil ST; Litzow MR
Curr Hematol Malig Rep; 2014 Jun; 9(2):165-73. PubMed ID: 24623281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
